Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

Weitere Dokumente

390585

Sigma-Aldrich

Suberohydroxamsäure

95%

Synonym(e):

N,N′-Dihydroxyoctanediamide, SBHA, Suberoyl bis-hydroxamic acid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Lineare Formel:
[-(CH2)3CONHOH]2
CAS-Nummer:
38937-66-5
Molekulargewicht:
204.22
MDL-Nummer:
MFCD00192455
UNSPSC-Code:
12352100
PubChem Substanz-ID:
24864150
NACRES:
NA.22

Qualitätsniveau

100

Assay

95%

mp (Schmelzpunkt)

153-155 °C (lit.)

SMILES String

ONC(=O)CCCCCCC(=O)NO

InChI

1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)

InChIKey

IDQPVOFTURLJPT-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 4

1 of 4

CI−994 ≥98% (HPLC), powder

Sigma-Aldrich

C0621

CI−994

Scriptaid ≥95%, solid

Sigma-Aldrich

S7817

Scriptaid

EX-527 ≥98% (HPLC)

Sigma-Aldrich

E7034

EX-527

5-Azacytidin ≥98% (HPLC)

Sigma-Aldrich

A2385

5-Azacytidin

Mohamed Rahmani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4849-4860 (2014-07-30)
The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse large B-cell lymphoma (DLBCL) cells. Various DLBCL cells were exposed to panobinostat
Jiansen Li et al.
Oncology reports, 37(1), 458-464 (2016-12-23)
Anaplastic thyroid cancer (ATC), usually derived from well-differentiated thyroid cancers is one of the most lethal human endocrine malignancies. In the present study, we report that in human ATC tumor tissue samples exist undetectable Notch1 and the active Notch1 intracellular
Li Ning et al.
The oncologist, 13(2), 98-104 (2008-02-29)
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability
Shuang Chen et al.
Blood, 124(17), 2687-2697 (2014-09-12)
Bim contributes to resistance to various standard and novel agents. Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics
Denisa Hrckova Drozdkova et al.
Anticancer research, 40(9), 4979-4987 (2020-09-04)
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.